What did Oppenheimer do in the March 09, 2026 TRVI analyst rating update?

Oppenheimer maintained an **Outperform** on TRVI on March 09, 2026 and advised buying weakness. The note did not include a new price target and was summarized by StreetInsider.

Does the March 09, 2026 action include a TRVI price target?

No. The Oppenheimer summary published March 09, 2026 on StreetInsider did not list a new TRVI price target, so no fresh numeric upside was provided in that note.

How should investors use the TRVI analyst rating now?

Treat the maintained Outperform as analyst conviction but not a standalone buy signal. Combine the TRVI analyst rating with pipeline milestones, cash runway, and your risk tolerance before acting.

What is Trevi Therapeutics’ market cap and recent trade change?

Trevi Therapeutics, Inc. has a market cap of **$1,500,290,988**. The March 09, 2026 memo noted a **price change since 0.09% ($0.01)** alongside the analyst commentary.

Analyst Ratings

Oppenheimer Maintains Outperform on TRVI (March 09, 2026)

ByHuzaifa Zahoor March 10, 2026

Oppenheimer maintained an Outperform on Trevi Therapeutics, Inc. (TRVI) on March 09, 2026 after a 10% near-term share drop. The TRVI analyst rating came with a clear buy-the-dip tone: Oppenheimer said, “We would buy today’s weakness.” This note was logged at 02:20 PM and referenced in StreetInsider coverage. Investors should note the firm left no new price target in the public note and recorded price change since 0.09% ($0.01). The market cap stands at $1,500,290,988.